5 stories mentioning HKG:6887Updated 22m ago
Every FINWIRES story that references HKG:6887, newest first.
Sunshine Lake Pharma (HKG:6887) said Zhang Yingjun was elected as chairman of the company's board, according to a Thursday filing with the Hong Kong bourse.The appointment will be effective until the company's next annual meeting.
Sunshine Lake Pharma (HKG:6887) said China's drug regulator accepted a clinical trial application for HEC-921, its experimental LY6G6D/4-1BB bispecific antibody for advanced solid tumors, according to a Thursday Hong Kong bourse filing.The company said the phase 1 study is expected to begin in 2026.HEC-921 is primarily being developed for LY6G6D-positive colorectal cancer, the filing said.
Sunshine Lake Pharma (HKG:6887) completed the conversion of nearly 208.4 million domestic shares into Hong Kong-listed shares on Thursday, according to a same-day filing with the Hong Kong bourse.The listing of the converted shares on the Hong Kong bourse is expected to begin at 9:00 am on Friday.
Sunshine Lake Pharma (HKG:6887) said the Hong Kong Stock Exchange has granted listing approval for its Hong Kong share full circulation application, according to a Wednesday bourse filing.Shares of the pharmaceutical firm were up nearly 1% in Thursday morning trade.The approval covers the conversion of about 208.4 million domestic shares into Hong Kong-listed shares.The converted shares represent about 36.1% of the company's total issued share capital.Upon completion, Hong Kong-listed shares will account for about 55.7% of the company's total share capital, up from 19.6% before the conversion.
Sunshine Lake Pharma's (HKG:6887) insulin glargine injection was approved by the U.S. Food and Drug Administration, the firm said Monday.The medicine, a biosimilar version of Sanofi's Lantus, is intended to treat children with type 1 diabetes and adults with type 2 diabetes.The injection will be available under the Langlara trade name.
